Loading…
20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis
Objectives: The current study identified patients with either essential thrombocythemia (ET) or polycythemia vera (PV) who have survived for at least 20 yr without the development of either acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) or myelofibrosis (MF) and compared their presenting...
Saved in:
| Published in: | European journal of haematology 2008-05, Vol.80 (5), p.386-390 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4058-e335c1ca53259fd37885c3627cc67ce1377ea4e824063b2c2259a1c406226aa53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4058-e335c1ca53259fd37885c3627cc67ce1377ea4e824063b2c2259a1c406226aa53 |
| container_end_page | 390 |
| container_issue | 5 |
| container_start_page | 386 |
| container_title | European journal of haematology |
| container_volume | 80 |
| creator | Tefferi, Ayalew Gangat, Naseema Wolanskyj, Alexandra P. Schwager, Susan Pardanani, Animesh Lasho, Terra L. Mesa, Ruben McClure, Rebecca F. Li, Chin-Yang Hanson, Curtis A. |
| description | Objectives: The current study identified patients with either essential thrombocythemia (ET) or polycythemia vera (PV) who have survived for at least 20 yr without the development of either acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) or myelofibrosis (MF) and compared their presenting features with those in whom these complications occurred in the first 10 yr of disease.
Methods: The study patients were selected from an institutional database of 1061 patients with either ET (n = 603) or PV (n = 458). In both instances, three distinct groups were delineated and their presenting features compared; group A included patients who have remained AML/MDS/MF free after a minimum follow‐up of 20 yr; groups B and C included patients who developed either AML/MDS or MF, respectively, in the first decade of their disease.
Results: The respective number of patients who fulfilled the above‐mentioned criteria for inclusion in groups A, B and C were 40, 12 and 8 for ET and 23, 18 and 12 for PV. In ET, compared with both groups B and C, group A displayed significantly fewer patients with less than normal hemoglobin level (P |
| doi_str_mv | 10.1111/j.1600-0609.2008.01038.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70496106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70496106</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4058-e335c1ca53259fd37885c3627cc67ce1377ea4e824063b2c2259a1c406226aa53</originalsourceid><addsrcrecordid>eNqNkM-O0zAQhy0EYkvhFZBPXFCyYzuxEyQOaLW0i1b8kYDlZrmuQ91N4mI7bHMCiTflSXBoVa744hnN75uRPoQwgZykd77NCQfIgEOdU4AqBwKsyvf30Ow0uI9mUAPNiqIgZ-hRCFsAoDURD9EZqSglrIYZ-kHh-e-fv0aP72zcuCHi1gy3prMaO48bu_Iupjp61YfG-U5F63pse2xCMH20qsVx4123cnqMm8Spidu5djz1341XL_DOm7XV0fmAVcRrq772LtjwGD1oVBvMk-M_R59eX368WGbX7xZXF6-uM11AWWWGsVITrUpGy7pZM1FVpWacCq250IYwIYwqTEUL4GxFNU0xRRLLKeUqYXP07LB35923wYQoOxu0aVvVGzcEKaCoOUnwHFWHoPYuBG8aufO2U36UBOQkX27l5FhOjuUkX_6VL_cJfXq8Maw6s_4HHm2nwMtD4M62ZvzvxfLyzXKqEp8deBui2Z945W8lF0yU8ubtQt4s3_PFB_5ZfmF_AGYWpN8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70496106</pqid></control><display><type>article</type><title>20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Tefferi, Ayalew ; Gangat, Naseema ; Wolanskyj, Alexandra P. ; Schwager, Susan ; Pardanani, Animesh ; Lasho, Terra L. ; Mesa, Ruben ; McClure, Rebecca F. ; Li, Chin-Yang ; Hanson, Curtis A.</creator><creatorcontrib>Tefferi, Ayalew ; Gangat, Naseema ; Wolanskyj, Alexandra P. ; Schwager, Susan ; Pardanani, Animesh ; Lasho, Terra L. ; Mesa, Ruben ; McClure, Rebecca F. ; Li, Chin-Yang ; Hanson, Curtis A.</creatorcontrib><description>Objectives: The current study identified patients with either essential thrombocythemia (ET) or polycythemia vera (PV) who have survived for at least 20 yr without the development of either acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) or myelofibrosis (MF) and compared their presenting features with those in whom these complications occurred in the first 10 yr of disease.
Methods: The study patients were selected from an institutional database of 1061 patients with either ET (n = 603) or PV (n = 458). In both instances, three distinct groups were delineated and their presenting features compared; group A included patients who have remained AML/MDS/MF free after a minimum follow‐up of 20 yr; groups B and C included patients who developed either AML/MDS or MF, respectively, in the first decade of their disease.
Results: The respective number of patients who fulfilled the above‐mentioned criteria for inclusion in groups A, B and C were 40, 12 and 8 for ET and 23, 18 and 12 for PV. In ET, compared with both groups B and C, group A displayed significantly fewer patients with less than normal hemoglobin level (P < 0.0001 and =0.02) or male sex (P = 0.005 and 0.05), respectively. On multivariable analysis, only anemia sustained its significance. A similar analysis in PV revealed an association between group B and leukocytosis using a leukocyte count threshold of either 10 or 15 × 109/L (P = 0.02).
Conclusion: The current study identifies PV patients with leukocytosis and ET patients with anemia as the most likely to undergo leukemic or fibrotic transformation.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/j.1600-0609.2008.01038.x</identifier><identifier>PMID: 18221390</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Female ; Fibrosis - pathology ; Humans ; JAK2 ; JAK2V617F ; leukemia ; Leukemia - pathology ; Male ; Middle Aged ; Polycythemia Vera - diagnosis ; Polycythemia Vera - epidemiology ; prognosis ; survival ; Thrombocythemia, Essential - diagnosis ; Thrombocythemia, Essential - epidemiology ; Time Factors ; V617F</subject><ispartof>European journal of haematology, 2008-05, Vol.80 (5), p.386-390</ispartof><rights>2008 The Authors</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4058-e335c1ca53259fd37885c3627cc67ce1377ea4e824063b2c2259a1c406226aa53</citedby><cites>FETCH-LOGICAL-c4058-e335c1ca53259fd37885c3627cc67ce1377ea4e824063b2c2259a1c406226aa53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18221390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tefferi, Ayalew</creatorcontrib><creatorcontrib>Gangat, Naseema</creatorcontrib><creatorcontrib>Wolanskyj, Alexandra P.</creatorcontrib><creatorcontrib>Schwager, Susan</creatorcontrib><creatorcontrib>Pardanani, Animesh</creatorcontrib><creatorcontrib>Lasho, Terra L.</creatorcontrib><creatorcontrib>Mesa, Ruben</creatorcontrib><creatorcontrib>McClure, Rebecca F.</creatorcontrib><creatorcontrib>Li, Chin-Yang</creatorcontrib><creatorcontrib>Hanson, Curtis A.</creatorcontrib><title>20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Objectives: The current study identified patients with either essential thrombocythemia (ET) or polycythemia vera (PV) who have survived for at least 20 yr without the development of either acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) or myelofibrosis (MF) and compared their presenting features with those in whom these complications occurred in the first 10 yr of disease.
Methods: The study patients were selected from an institutional database of 1061 patients with either ET (n = 603) or PV (n = 458). In both instances, three distinct groups were delineated and their presenting features compared; group A included patients who have remained AML/MDS/MF free after a minimum follow‐up of 20 yr; groups B and C included patients who developed either AML/MDS or MF, respectively, in the first decade of their disease.
Results: The respective number of patients who fulfilled the above‐mentioned criteria for inclusion in groups A, B and C were 40, 12 and 8 for ET and 23, 18 and 12 for PV. In ET, compared with both groups B and C, group A displayed significantly fewer patients with less than normal hemoglobin level (P < 0.0001 and =0.02) or male sex (P = 0.005 and 0.05), respectively. On multivariable analysis, only anemia sustained its significance. A similar analysis in PV revealed an association between group B and leukocytosis using a leukocyte count threshold of either 10 or 15 × 109/L (P = 0.02).
Conclusion: The current study identifies PV patients with leukocytosis and ET patients with anemia as the most likely to undergo leukemic or fibrotic transformation.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Female</subject><subject>Fibrosis - pathology</subject><subject>Humans</subject><subject>JAK2</subject><subject>JAK2V617F</subject><subject>leukemia</subject><subject>Leukemia - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Polycythemia Vera - diagnosis</subject><subject>Polycythemia Vera - epidemiology</subject><subject>prognosis</subject><subject>survival</subject><subject>Thrombocythemia, Essential - diagnosis</subject><subject>Thrombocythemia, Essential - epidemiology</subject><subject>Time Factors</subject><subject>V617F</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqNkM-O0zAQhy0EYkvhFZBPXFCyYzuxEyQOaLW0i1b8kYDlZrmuQ91N4mI7bHMCiTflSXBoVa744hnN75uRPoQwgZykd77NCQfIgEOdU4AqBwKsyvf30Ow0uI9mUAPNiqIgZ-hRCFsAoDURD9EZqSglrIYZ-kHh-e-fv0aP72zcuCHi1gy3prMaO48bu_Iupjp61YfG-U5F63pse2xCMH20qsVx4123cnqMm8Spidu5djz1341XL_DOm7XV0fmAVcRrq772LtjwGD1oVBvMk-M_R59eX368WGbX7xZXF6-uM11AWWWGsVITrUpGy7pZM1FVpWacCq250IYwIYwqTEUL4GxFNU0xRRLLKeUqYXP07LB35923wYQoOxu0aVvVGzcEKaCoOUnwHFWHoPYuBG8aufO2U36UBOQkX27l5FhOjuUkX_6VL_cJfXq8Maw6s_4HHm2nwMtD4M62ZvzvxfLyzXKqEp8deBui2Z945W8lF0yU8ubtQt4s3_PFB_5ZfmF_AGYWpN8</recordid><startdate>200805</startdate><enddate>200805</enddate><creator>Tefferi, Ayalew</creator><creator>Gangat, Naseema</creator><creator>Wolanskyj, Alexandra P.</creator><creator>Schwager, Susan</creator><creator>Pardanani, Animesh</creator><creator>Lasho, Terra L.</creator><creator>Mesa, Ruben</creator><creator>McClure, Rebecca F.</creator><creator>Li, Chin-Yang</creator><creator>Hanson, Curtis A.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200805</creationdate><title>20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis</title><author>Tefferi, Ayalew ; Gangat, Naseema ; Wolanskyj, Alexandra P. ; Schwager, Susan ; Pardanani, Animesh ; Lasho, Terra L. ; Mesa, Ruben ; McClure, Rebecca F. ; Li, Chin-Yang ; Hanson, Curtis A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4058-e335c1ca53259fd37885c3627cc67ce1377ea4e824063b2c2259a1c406226aa53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Female</topic><topic>Fibrosis - pathology</topic><topic>Humans</topic><topic>JAK2</topic><topic>JAK2V617F</topic><topic>leukemia</topic><topic>Leukemia - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Polycythemia Vera - diagnosis</topic><topic>Polycythemia Vera - epidemiology</topic><topic>prognosis</topic><topic>survival</topic><topic>Thrombocythemia, Essential - diagnosis</topic><topic>Thrombocythemia, Essential - epidemiology</topic><topic>Time Factors</topic><topic>V617F</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tefferi, Ayalew</creatorcontrib><creatorcontrib>Gangat, Naseema</creatorcontrib><creatorcontrib>Wolanskyj, Alexandra P.</creatorcontrib><creatorcontrib>Schwager, Susan</creatorcontrib><creatorcontrib>Pardanani, Animesh</creatorcontrib><creatorcontrib>Lasho, Terra L.</creatorcontrib><creatorcontrib>Mesa, Ruben</creatorcontrib><creatorcontrib>McClure, Rebecca F.</creatorcontrib><creatorcontrib>Li, Chin-Yang</creatorcontrib><creatorcontrib>Hanson, Curtis A.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tefferi, Ayalew</au><au>Gangat, Naseema</au><au>Wolanskyj, Alexandra P.</au><au>Schwager, Susan</au><au>Pardanani, Animesh</au><au>Lasho, Terra L.</au><au>Mesa, Ruben</au><au>McClure, Rebecca F.</au><au>Li, Chin-Yang</au><au>Hanson, Curtis A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2008-05</date><risdate>2008</risdate><volume>80</volume><issue>5</issue><spage>386</spage><epage>390</epage><pages>386-390</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Objectives: The current study identified patients with either essential thrombocythemia (ET) or polycythemia vera (PV) who have survived for at least 20 yr without the development of either acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) or myelofibrosis (MF) and compared their presenting features with those in whom these complications occurred in the first 10 yr of disease.
Methods: The study patients were selected from an institutional database of 1061 patients with either ET (n = 603) or PV (n = 458). In both instances, three distinct groups were delineated and their presenting features compared; group A included patients who have remained AML/MDS/MF free after a minimum follow‐up of 20 yr; groups B and C included patients who developed either AML/MDS or MF, respectively, in the first decade of their disease.
Results: The respective number of patients who fulfilled the above‐mentioned criteria for inclusion in groups A, B and C were 40, 12 and 8 for ET and 23, 18 and 12 for PV. In ET, compared with both groups B and C, group A displayed significantly fewer patients with less than normal hemoglobin level (P < 0.0001 and =0.02) or male sex (P = 0.005 and 0.05), respectively. On multivariable analysis, only anemia sustained its significance. A similar analysis in PV revealed an association between group B and leukocytosis using a leukocyte count threshold of either 10 or 15 × 109/L (P = 0.02).
Conclusion: The current study identifies PV patients with leukocytosis and ET patients with anemia as the most likely to undergo leukemic or fibrotic transformation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18221390</pmid><doi>10.1111/j.1600-0609.2008.01038.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2008-05, Vol.80 (5), p.386-390 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70496106 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Aged Aged, 80 and over Female Fibrosis - pathology Humans JAK2 JAK2V617F leukemia Leukemia - pathology Male Middle Aged Polycythemia Vera - diagnosis Polycythemia Vera - epidemiology prognosis survival Thrombocythemia, Essential - diagnosis Thrombocythemia, Essential - epidemiology Time Factors V617F |
| title | 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A15%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=20+%E2%80%83yr%20without%20leukemic%20or%20fibrotic%20transformation%20in%20essential%20thrombocythemia%20or%20polycythemia%20vera:%20predictors%20at%20diagnosis&rft.jtitle=European%20journal%20of%20haematology&rft.au=Tefferi,%20Ayalew&rft.date=2008-05&rft.volume=80&rft.issue=5&rft.spage=386&rft.epage=390&rft.pages=386-390&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/j.1600-0609.2008.01038.x&rft_dat=%3Cproquest_cross%3E70496106%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4058-e335c1ca53259fd37885c3627cc67ce1377ea4e824063b2c2259a1c406226aa53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70496106&rft_id=info:pmid/18221390&rfr_iscdi=true |